Phase 3RecruitingINTERVENTIONAL
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
ClinicalTrials.gov · NCT07446439 · Registry updated: 2026-04-20
- Condition / research focus
- Nausea and Vomiting; Obesity
- Sponsor
- Vanda Pharmaceuticals
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2026-03-27. Completion: 2026-12-01 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Tradipitant (drug) — also listed as: Nereus, VLY-686
- Placebo (drug)
Where the study takes place — 10 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Vanda Investigational Site
Los Angeles, California, United States
Site recruitment: Recruiting - Vanda Investigational Site
San Diego, California, United States
Site recruitment: Recruiting - Vanda Investigational Site
San Jose, California, United States
Site recruitment: Not yet recruiting - Vanda Investigational Site
Tampa, Florida, United States
Site recruitment: Recruiting - Vanda Investigational Site
Hamilton, New Jersey, United States
Site recruitment: Not yet recruiting - Vanda Investigational Site
New York, New York, United States
Site recruitment: Not yet recruiting - Vanda Investigational Site
Syosset, New York, United States
Site recruitment: Not yet recruiting - Vanda Investigational Site
Plano, Texas, United States
Site recruitment: Not yet recruiting - Vanda Investigational Site
San Antonio, Texas, United States
Site recruitment: Not yet recruiting - Vanda Investigational Site
Burke, Virginia, United States
Site recruitment: Not yet recruiting